Register or Sign in to Save this opportunity, or Send an Inquiry.
Droglican® - Chondroitin Sulfate 200 Mg / Glucosamine Hydrochloride 250 Mg Hard Capsules.
Bioiberica Spain flag Spain
Abstract ID:
The first association chondroitin / glucosamine authorized as drug in Europe.
Send an Inquiry
RE:
Participants
You
Introduction/Background
Chondroitin sulfate is one of the main elements that form cartilage and combines with a central protein, forming proteoglycan, which gives cartilage its mechanical and elastic properties. The therapeutic activity of chondroitin sulfate in patients with osteoarthritis is due to several factors: anti-inflammatory activity [measured by the interleukin inhibition-1 (IL-1), metaloprotease-3 (MMP-3) and prostaglandin E2 (PGE2)]; stimulation of the synthesis of proteoglicans and hyaluronic acid; inhibition of the cartilage's proteolytic enzymes (including collagenase, elastase, proteoglycanase, phospholipase A2, N-acetylglucosaminidase, etc.) and inhibition of the nuclear translocation of the nuclear factor kappa B (NF-êB) involved in certain chronic inflammatory processes.

Glucosamine is an endogenous substance and a normal constituent of the polysaccharide chain of the cartilage matrix and of the glycosaminoglycans of the synovial liquid. In vitro and in vivo studies have demonstrated that glucosamine stimulates the physiological synthesis of glycosaminoglicans and proteoglycans by means of chondrocytes and of hyaluronic acid by means of sinoviocytes. Subsequent studies have shown that glucosamine can inhibit the synthesis of certain substances like superoxide radicals and the activity of the lysosomal enzymes and of the joint cartilage destroying enzymes such as collagenase and phospholipase A2.

It has been observed that chondroitin sulfate and glycosamine hydrochloride promote the formation of new cartilage in vitro by means of stimulation of the synthesis of collagen and proteoglycans; an effect that presents synergy when both are used in combination.

Description of Technology
• Droglican® is the first and only association chondroitin-glucosamine authorized as drug in Europe.

• Droglican® is composed of chondroitin sulfate, a polysaccharide of the glycosaminoglycans group (in the form of glucosamine hydrochloride), a natural amino monosaccharide.

• Droglican® is indicated for the symptomatic treatment of osteoarthritis of the knee in patients with moderate to severe pain in which treatment combined with chondroitin sulfate and glucosamine is indicated.

• Authorized and commercialized in Spain.
Type of Business Relationship Sought
Currently under registration in several countries of Europe. Available for out-licensing.
FEATURED
Last Updated Nov 2017
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION

Opportunity Contact